Assenagon Asset Management S.A. Supernus Pharmaceuticals, Inc. Transaction History

Assenagon Asset Management S.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 17, 2024	BUY	$22.72 - $29.68 $823,690 - $1.08 Million	36,254 New	36,254 $1.05 Million
Q1 2023 Apr 18, 2023	SELL	$34.93 - $42.03 $3.95 Million - $4.75 Million	-113,121 Reduced 67.33%	54,889 $1.99 Million
Q4 2022 Jan 12, 2023	BUY	$31.09 - $37.88 $3.91 Million - $4.77 Million	125,795 Added 297.99%	168,010 $5.99 Million
Q2 2022 Jul 27, 2022	BUY	$25.33 - $34.25 $1.07 Million - $1.45 Million	42,215 New	42,215 $1.22 Million
Q1 2022 Apr 25, 2022	SELL	$28.51 - $32.9 $1.98 Million - $2.28 Million	-69,389 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$26.37 - $34.22 $1.83 Million - $2.37 Million	69,389 New	69,389 $2.02 Million
Q1 2019 Apr 26, 2019	SELL	$32.77 - $41.99 $219,624 - $281,416	-6,702 Closed	0 $0
Q4 2018 Jan 23, 2019	BUY	$30.84 - $49.51 $206,689 - $331,816	6,702 New	6,702 $223,000

286

60.7M

27.7K

11.3K

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $2.14B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

Stay updated on Assenagon Asset Management S.A. with notifications on news.